← Trials/Trial dossier/NCT03889496

GLP1-ex-vivo

TerminatedPhase NA

Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin

Lead sponsor

Radboud University Medical Center

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Correlation between the tracer uptake (counts) and beta cell mass (mg)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03889496

Org study IDNL47132.091.14

Timeline

Milestones

Study start2015-11-16actual

Study first posted2019-03-26actual

Primary completion2021-06-14actual

Study completion2021-06-14actual

Last update posted2023-07-12actual

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Scheduled for partial or complete pancreatectomy or Whipple procedure at Radboudumc

Exclusion criteria

•Resection that provides insufficient amount of tissue

•Previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl- Peptidase IV inhibitors

•Breast feeding

•Pregnancy or the wish to become pregnant within 6 months

•Renal disease

•Liver disease

•Age < 18 years

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Correlation between the tracer uptake (counts) and beta cell mass (mg)

Time frame:4 years

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.
EJNMMI research2024 Oct 15PMID39405026doi:10.1186/s13550-024-01159-6via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.